Progestin Microarray Patch
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Intradermal
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Cardiff University, InnoCore Pharmaceuticals
- Contact: Prof. James Birchall, PhD - Cardiff University
Details
- API: Progestin - Release Model Developed with Levonorgestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: MAPs in general have a number of well-documented potential advantages - ease of use, potential for affordability, desirable max duration, shelf stable.
Product Status
Active Late-Stage Non-Clinical Development
History
2021: Cardiff University publishes results of human-centered design effort to refine prototype of a progestin-only microarray contraceptive patch
2022: Cardiff University publishes results of evaluation intending to formalize LNG release models and characteristics for microneedle-based drug delivery systems.
2024: Cardiff University receives additional funding from the Gates Foundation to support the development of a microneedle platform to deliver longer-acting contraceptive drugs.